Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-CIDEB in Adults With Fibrotic MASH
NCT07631637Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jan 2029
- Countries
- 2
01
Overview
A Phase 2 trial of ALN-CIDEB in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Regeneron Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
ALN-CIDEB
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07631637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631637.